-
Study aim
-
To evaluate the effects of the Fenelis herbal formulation (a combination of Melissa officinalis, Foeniculum vulgare, and Golghand) on the severity, frequency, and duration of hot flashes in postmenopausal women.
-
Design
-
Single-arm, before-after, triple-blind, phase 2 clinical trial conducted on 20 participants (15 completers) in selected healthcare centers in Isfahan, Iran. Random allocation was not applicable due to the single-arm design.
-
Settings and conduct
-
The trial was conducted in selected healthcare centers in Isfahan Province, Iran, from March 2020 to March 2021. Participants recorded hot flash events for one week at baseline, followed by three weeks of Fenelis capsule administration. Participants, care providers, and outcome assessors were blinded to the study hypotheses and expected outcomes. Data were coded prior to statistical analysis to blind the data analyst.
-
Participants/Inclusion and exclusion criteria
-
Menopausal women aged 45 to 64 years with hot flash complaints were included. Women with a history of hormone therapy in the past 3 months, use of herbal supplements for menopausal symptoms, surgical menopause, known allergy to Fenelis components, or serious chronic disease were excluded.
-
Intervention groups
-
Intervention group: Participants received Fenelis herbal capsules (containing Melissa officinalis, Foeniculum vulgare, and Golghand) for three weeks following one week of baseline hot flash recording.
-
Main outcome variables
-
Hot flash frequency (daily count); hot flash severity (mild, moderate, severe, very severe); hot flash duration; quality of life score (Greene scale); anxiety and depression score (Greene scale).